Items tagged with Access
Time to lower the price of Xpert cartridges to $5 (post with simple image)
Advocates request Cepheid immediately reduce the price of Xpert tests to $5, inclusive of service and maintenance; Cepheid claims costs for each Xpert cartridge "substantially exceed" the requested price target of $5, but does not provide evidence to support this claim.
DR-TB Drugs Under the Microscope, 6th edition (post with simple image)
Médecins Sans Frontières releases the 6th edition of DR-TB Drugs Under the Microscope: 5 Urgent Actions to Improve DR-TB Treatment.
Civil society demands affordability, transparency and accountability from the TB Alliance (post with simple image)
Civil society activists storm the stage at The Union Conference to demand affordability, transparency and accountability from the TB Alliance.
TB activists disrupt opening of The Union Conference to protest drug corporations keeping life-saving medicines from people (post with simple image)
Newer medicines for drug-resistant TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world.
Price announced for new lifesaving TB drug pretomanid still too high (post with simple image)
Pretomanid is just one part of a regimen of multiple drugs that people need. MSF has been calling for the price of a complete DR-TB treatment course to be no higher than $500 per person.
Civil society statement on rifapentine price discount (post with simple image)
A lower price for rifapentine is just a start — communities need more than discounts to access TB preventive therapy!
Protestors demand Cepheid halve the price of GeneXpert TB tests to US$5 (post with simple image)
The high cost of GeneXpert tests for TB leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.
Public investments in TB medicine bedaquiline far exceed those of developer Johnson & Johnson (post with simple image)
Quantification of investments in the development of bedaquiline finds total public and philanthropic expenditures are three to five times those of Johnson & Johnson.
TAG applauds Indian TB activists in opposing patents for critical TB prevention drugs (post with simple image)
Civil society takes legal action to contest patent applications filed by Sanofi on fixed-dose combinations of two decades-old drugs used to prevent TB.
TB Alliance responds to questions raised by activists in relation to pretomanid (post with simple image)
MSF, TAG and TB CAB raised a number of outstanding medical and research questions regarding pretomanid and the regimen BPaL.
Page 65 of 67 · Total posts: 0←First 64 65 66 Last→